Lilly’s Kisunla Set To Give Leqembi A Run For Its Money In Early Alzheimer’s

Donanemab Has Dosing, Cost Advantages Over Eisai/Biogen Drug

 
• By Mandy Jackson
  
Abstract digital technology brain futuristic, AI Artificial intelligence blue background, Cyber science health tech
The path to anti-amyloid treatment remains long but more centers are prepared to treat • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip